Adding Tobramycin to Vancomycin Powder Does Not Reduce Tibial Fracture Infections

Fracture-related infections remain a devastating complication in orthopedic trauma, leading to increased morbidity, prolonged hospital stays, and the potential need for amputation [1, 2]. To mitigate this risk, surgeons increasingly rely on local antibiotic delivery systems, such as intrawound powders or antibiotic-impregnated calcium sulfate, to achieve high tissue concentrations without systemic toxicity [3]. While local vancomycin administration has become a common prophylactic strategy to target gram-positive pathogens in high-risk fractures, the optimal regimen remains heavily debated [4, 5]. Because complex periarticular injuries often face polymicrobial threats, clinicians frequently consider adding agents with gram-negative coverage, though the clinical efficacy of this dual-powder approach has lacked rigorous validation. A newly published randomized clinical trial of 1528 patients now provides clear evidence that adding 1.2 g of intrawound tobramycin to 1.0 g of vancomycin does not reduce deep surgical site infections compared with vancomycin alone (7.4% versus 6.6%; hazard ratio, 1.11) in high-risk tibial fractures [6].